Sunderland-based science company Complement Genomics Ltd (CGL) has entered into a partnership with a leading US provider of genomic services for clinical trials and research, in order to conduct studies to improve the lives of those suffering from a variety of debilitating illnesses.
By partnering with Expression Analysis Inc., CGL will gain access to technology unprecedented elsewhere in the UK, allowing them to screen large numbers of patients with specific conditions, identifying genes associated with neurodegenerative disease and other conditions including cancer, diabetes and Parkinson’s.
Louise Allcroft, Chief Executive Officer of CGL, says: “The high-volume, whole genome approach we can now adopt has been fundamental in improving scientists’ understanding of complex disorders. It will allow us to gain further insight into the involvement of genes in the manifestation of many diseases, and contribute not only to the development of new diagnostic tests but also aid the development and design of new modes of treatment.”
Expression Analysis Inc. is a leading international provider of genomic services in clinical trials and research, offering experimental design consultation, biologic sample preparation, sample processing and data analysis services to clients worldwide.
Steve McPhail, President and CEO of Expression Analysis, says: “The partnership with CGL and their Geneblitz service provides us with an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms.”
CGL operates a successful paternity testing division under the brand name, dadcheck, as well as providing a comprehensive range of services to the biotechnology sector such as genotyping, DNA sequencing, forensic testing and a number of toxicology and drug analysis protocols in addition to its own research programs in wound care.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.